Considering pharmacological inhibition of CaMKII and activation of the ERK1/2 and PI3K/AKT protected cardiomyocytes from apoptosis during simulated ischemia in vitro, we chose these three pathways as the main targets in our study [22, 23]. The gene discussed is MAPK3; the disease is ischemia.